NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 8 February 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair, Topic 1) Items 1.1 to 4.2.2
2. Dr Megan John (Chair, Topics 2 & 3) Present for all items
3. Dr Raju Reddy (Vice-chair) Present for all items
4. Martin Bradley Present for all items
5. Dr Matthew Bradley Present for all items
6. Paul Caulfield Present for all items
7. Elliott Dash Present for all items
8. Professor Sofia Dias Present for all items
9. Andrew Fox Present for all items
10. Christopher Herring Present for all items
11. Dr Robert Hodgson Present for all items
12. Dr Bernard Khoo Present for all items
13. Dr Ivan Koychev Items 5.1.1 to 5.2.2
14. Dr Guy Makin Present for all items
15. Professor David Meads Present for all items
16. Giles Monnickendam Present for all items
17. Dr Nathan Moore Present for all items
18. Dr Paula Parvulescu Present for all items
19. Dr Rebecca Payne Present for all items
20. Carole Pitkeathley Present for all items
21. Dr Ben Searle Present for all items
22. Will Sullivan Present for all items
23. Dr Zenas Yiu Items 1.1 to 4.2.2

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Jasdeep Hayre, Associate Director Items 1.1 to 5.2.2

Celia Mayers, Project Manager Items 1.1 to 4.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Kirsty Pitt, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Louise Jafferally, Project Manager Items 5.1.1 to 5.2.2

Sally Doss, Heath Technology Assessment Adviser Items 5.1.1 to 5.2.2

Luke Cowie, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

Linda Landells, Associate Director Items 6.1.1 to 6.1.3

Kate Moore, Project Manager Items 5.1.3 to 6.1.3

Nigel Gumbleton, Heath Technology Assessment Adviser Items 6.1.1 to 6.1.3

Emily Leckenby, Heath Technology Assessment Analyst Items 6.1.1 to 6.1.3

External assessment group representatives present

Nicole Downes, BMJ-TAG Items 1.1 to 4.1.3

Isaac Mackenzie, BMJ-TAG Items 1.1 to 4.1.3

Dr Dwayne Boyers, University of Aberdeen Items 5.1.1 to 5.1.3

Dr Neil Scott, University of Aberdeen Items 5.1.1 to 5.1.3

Clinical & Patient experts present

Steph Weatherley, Information and Support Adviser – patient expert, nominated by The Migraine Trust Items 1.1 to 4.1.3

Debbie Shipley, Head of Information and Support Services – patient expert, nominated by The Migraine Trust Items 1.1 to 4.1.3

Dr Nicola Giffin, Consultant Neurologist, Chair of Association of British Neurologists headache and pain advisory group – clinical expert, nominated by Association of British Neurologists Items 1.1 to 4.1.3

Dr Brendan Davies, Consultant Neurologist, Clinical lead, Midlands Regional Headache clinic – clinical expert, nominated by AbbVie Items 1.1 to 4.1.3

Professor Anthony Khawaja, Honorary Consultant Ophthalmic Surgeon & Associate Professor – clinical expert nominated by Santen

Items 5.1.1 to 5.1.3

Neeru Vallabh, Ophthalmologist / Clinical Senior Lecturer – clinical expert nominated by Santen

Items 5.1.1 to 5.1.3

Joanna Hodgkinson, Head of Support Services, Glaucoma UK – patient expert nominated by Glaucoma UK

Items 5.1.1 to 5.1.3

Julia Margetts, Patient expert nominated by Glaucoma UK

Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Paul Arundel, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Dr Andrew Hitchings and Philip Mallender.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 11 January 2024

### Appraisal of Atogepant for preventing migraine [ID5090]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public, and company representatives from AbbVie.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10992).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Paul Caulfield, Martin Bradley, and Dr Robert Hogson.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10992>

### Appraisal of Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Santen.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10741).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Sofia Dias, Dr Ivan Koychev, and Paul Caulfield.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10741>

### Appraisal of Voxelotor for treating haemolytic anaemia caused by sickle cell disease [ID1403]

* 1. Closed session with committee members and NICE staff only.
     1. The Chair asked all committee members and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10505).
     2. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     3. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10505>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 6 March 2024 and will start promptly at 09:00am.